Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $13.50 USD
Change Today -0.27 / -1.96%
Volume 112.9K
As of 8:10 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

750 Lexington Avenue

Eleventh Floor

New York, NY 10022

United States

Phone: 646-502-2311

Fax: 646-389-0968

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The company is developing two clinical-stage product candidates, SL-401 and SL-701. Product Candidates SL-401—A Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R) on CSCs and Tumor Bulk SL-401 is a clinically active targeted therapy directed to the IL-3R, which is overexpressed on CSCs and/or various mature cancer cells derived from CSCs (tumor bulk) of multiple hematologic cancers, including acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, certain lymphomas, including Hodgkin’s disease, multiple myeloma, and multiple rare hematologic malignancies, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), and others. SL-401 has demonstrated single-agent activity, including durable complete responses, in investigator sponsored Phase 1/2 trials in various indications, including BPDCN and relapsed or refractory acute myeloid leukemia. The company intends to advance SL-401 into corporate sponsored trials for multiple hematologic cancer indications, including BPDCN, where it intends to pursue a Phase 2 registration-directed path. The company also intends to initiate trials in additional rare IL-3R+ malignancies, including mastocytosis, hypereosinophilic syndrome, other myeloproliferative syndromes, and hairy cell leukemia. SL-701—A Subcutaneously-Administered Cancer Vaccine (Synthetic Peptides) SL-701, a clinically active therapeutic cancer vaccine consisted of multiple synthetic peptides, is designed to direct the immune system to attack targets present on the CSCs and tumor bulk of brain cancer. The company intends to advance SL-701 into a corporate sponsored Phase 2 trial in adults, as well as a cooperative group led study in children. It also intends to pursue a Phase 2 trial of SL-701 in pediatric patients with brainstem and non-brainstem high-grade glioma, which are also areas of unmet medical need. In an investigator sponsored Phase 1/2 clinical trial, the vaccine, being developed by the company as SL-701, is evaluated in adult patients with recurrent or refractory high-grade glioma. License and Research Agreements The company has a research and license agreement with Scott and White Memorial Hospital for SL-401, its biologic targeted therapy directed to the IL-3R. Under the agreement, Scott and White Memorial Hospital has granted the company an exclusive, royalty-bearing, worldwide license under certain patent rights, know-how and materials to research, develop, make, have made, formulate, use, sell, offer to sell and import SL-401, and any products containing or comprising such compound in finished dosage pharmaceutical form, for the diagnosis, prophylaxis and/or treatment of any disease or condition in humans or animals. The company has an exclusive license agreement with the University of Pittsburgh for the composition of matter, and use with other components, of a proprietary immunogenic mutant analog peptide of IL-13Ra2, an active ingredient of SL-701, its brain cancer vaccine candidate. Under the agreement, the University of Pittsburgh grants the company an exclusive worldwide license under certain patent rights to make, have made, use, sell and import brain cancer peptide antigen vaccines (including SL-701, which has been developed by the University of Pittsburgh under a separate vaccine name designated by the University of Pittsburgh). The company has a non-exclusive license agreement with the University of Pittsburgh for the use of EphA2 epitopes, another active ingredient of SL-701. Under the agreement, the University of Pittsburgh grants the company a non-exclusive worldwide license under certain patent rights to use the EphA2 peptide in or packaged with the IL-13Ra2 peptide, as well as other vaccines that the company might develop and own or exclusively control, for the diagnosis, treatment or prevention of diseases and tumors of the brain in human patients. The company also has a non-exclusive license agreement w

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STML:US $13.50 USD -0.27

STML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for STML.
View Industry Companies

Industry Analysis


Industry Average

Valuation STML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 592.0x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 398.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMLINE THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at